Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Takeda Pharmaceutical offers milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced it has received a $1 million milestone payment from Takeda Pharmaceutical Company Limited for achieving a pre-established preclinical milestone under the companies' 2006 collaboration agreement, which also calls for additional future milestone payments and royalties on product sales.

16 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

2010 UCBeyond Scholarship Program launched to help students living with chronic illnesses

UCB Canada Inc. is proud to announce the launch of the 2010 UCBeyond Scholarship Program. During its four-year lifespan, the UCBeyond Scholarship has allocated almost 70 educational bursaries worth close to $350,000.00 CAN to students living with chronic illnesses such as rheumatoid arthritis, Crohn's disease and epilepsy.

15 Apr 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

Study identifies pathway linked to rheumatoid arthritis

Investigators from Hospital for Special Surgery have identified a pathway involved in turning off inflammation that does not work properly in people with inflammatory arthritis. The finding, reported in the April 23 issue of the journal Immunity, could lead to the development of new therapeutic approaches to treating arthritis in the future.

13 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Three nonprofit organizations launch campaign to increase national awareness of PF

The Coalition for Pulmonary Fibrosis, The Pulmonary Fibrosis Foundation and the Pulmonary Fibrosis Association of Texas today announced the launch of a special, grassroots campaign to build increased national awareness of Pulmonary Fibrosis.

12 Apr 2010

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Women need to be educated on osteoporosis risk factors and treatment: Study

Underscoring what researchers call a serious global public health concern, results from a new study led by Columbia University Medical Center reveal that many women at an elevated level of risk for osteoporosis-associated fractures fail to perceive the implications of the risk factors.

8 Apr 2010

Women living in northeastern U.S. more likely to develop RA: Study

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Boston University School of Public Health researcher.

8 Apr 2010

$Women unaware of risk of dangerous osteoporosis fractures$

Women unaware of risk of dangerous osteoporosis fractures

Only one in three Australian women diagnosed with osteoporosis are aware they are at higher risk of sustaining debilitating bone fractures, according to a landmark international study published with input from University of Sydney researchers.

7 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010.

5 Apr 2010

Study highlights need for public education on osteoporosis risk factors and treatment

Underscoring what researchers call a serious international public health concern, results from the Global Longitudinal Study of Osteoporosis in Women (GLOW) showed that among women at an elevated level of risk for osteoporosis-associated fractures, there is a failure to perceive the implications of having important risk factors.

3 Apr 2010

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

A new study reveals an exciting potential benefit of the rapidly accumulating databases of health care information, the ability to make unprecedented links between genomic data and clinical medicine. The research, published by Cell Press in the April issue of the American Journal of Human Genetics, supports the idea that large scale DNA databanks linked to electronic medical record (EMR) systems provide a valuable platform for discovering, assessing and validating associations between genes and diseases.

2 Apr 2010

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Takeda Pharmaceutical offers milestone payment to XOMA

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

2010 UCBeyond Scholarship Program launched to help students living with chronic illnesses

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

XOMA expands anti-inflammatory antibody intellectual property portfolio

Study identifies pathway linked to rheumatoid arthritis

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Three nonprofit organizations launch campaign to increase national awareness of PF

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

"Nanovaccine" reverses diabetes

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Nanotechnology-based vaccine cures mice with type 1 diabetes

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Women need to be educated on osteoporosis risk factors and treatment: Study

Women living in northeastern U.S. more likely to develop RA: Study

Women unaware of risk of dangerous osteoporosis fractures

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

Study highlights need for public education on osteoporosis risk factors and treatment

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in